Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REPOTRECTINIB vs RESLIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REPOTRECTINIB vs RESLIZUMAB: Safety Overview

Metric REPOTRECTINIB RESLIZUMAB
Total FAERS Reports 187 621
Deaths Reported 27 15
Death Rate 14.4% 2.4%
Hospitalizations 48 121
Average Patient Age 60.8 yrs 55.9 yrs
% Female Patients 61.1% 63.2%
FDA Approval Date Jun 11, 2024 N/A
Manufacturer E.R. Squibb & Sons, L.L.C. Teva Respiratory, LLC
Route ORAL INTRAVENOUS
Marketing Status Prescription Prescription